Ataxia telangiectasia is one of those rarest of the rare diseases caused by an anomaly in the genetic coding of a human. It creates deformities in the control center of the brain, the cerebellum causing major disabilities in the body. This ailment is also known as Louis-Bar syndrome or Boder-Sedgwick syndrome. It makes a serious dent in the immune power of the person, making him vulnerable to frequent infections. In many cases this makes the victim vulnerable to cancer and other respiratory system infections. Ataxia telangiectasia is caused by sequence disruption in the gene named ATM (Ataxia telangiectasia mutated). It is an autosomal (relating to one of the 23 chromosomes other than the sex chromosome) recessive disease which means that it will not affect the body unless it has twin copies of the recessive genetic anomaly. Therefore if both the parents carry one copy of the gene, they themselves won't be affected by it, but they will be carriers. All traits in the human body are expressions of genes. Every trait has a dominant and recessive factor in the genes. The gene causing ataxia telangiectasia being autosomal recessive, there is a chance that one out of four children of carrier … Continue reading →

Summary: ViroPharma's third quarter net income of $0.07 per share beat the Zacks Consensus Estimate by a penny. Quarterly revenues increased 24.2% year over year to $113.1 million, in line with the Zacks Consensus Estimate. The increase in revenues was fuelled by strong growth of Cinryze in the U.S. Shire announced that it will acquire ViroPharma for approximately $50 per share or $4.2 billion. We have downgraded our recommendation on ViroPharma to Neutral from Outperform. The company's shares surged significantly in the past few months on potential buyout rumors. However, with the news of Shire acquiring ViroPharma announced last month, the share price has already touched the offer price of $50. Hence, there is no potential for any further increase. Overview: Incorporated in Delaware in 1994, ViroPharma Incorporated (VPHM) is an international biotechnology company. Headquartered in Pennsylvania, the company develops and commercializes drugs specifically targeting unmet medical needs with particular focus on orphan diseases. Key drugs for the company include Cinryze for hereditary angioedema (HAE), Plenadren for the treatment of adrenal insufficiency (AI), Buccolam in Europe for the treatment of pediatric seizures, and Vancocin indicated for the treatment of C. difficile- associated diarrhea (CDAD). Interesting candidates in ViroPharma's pipeline include … Continue reading →

ANN ARBOR Many primary care pediatricians say they feel uncomfortable providing health care to patients with genetic disorders. Also, many do not consistently discuss all risks and benefits of genetic tests with patients, according to research published recently in the American Journal of Medical Genetics. Investigators from the University of Michigans C.S. Mott Childrens Hospital and The Childrens Hospital at Montefiore (CHAM) conducted a national survey of 88 physicians who are part of the American Academy of Pediatrics Quality Improvement Innovation Networks, assessing their comfort level ordering genetic tests for their pediatric patients, their attitudes toward genetic medical care and their choices regarding taking family histories. The majority of those physicians reported ordering few genetic tests (three or less times) per year, excluding newborn screening which is federally mandated for all newborns; few (13 percent) strongly agreed that they discussed the potential risks, benefits, and limitations of genetic tests with all their patients and only half felt competent in providing healthcare to patients with genetic disorders. While genetics has historically been viewed as a discipline focused on rare conditions, recent genomic advances have highlighted that genetics has a role in common conditions encountered in primary care medicine, said Dr. Beth … Continue reading →

Stem Cell Therapy: Hip Pain Meet a real patient who suffered from extreme hip pain. Learn her story, and how traditional approaches could not identify or treat the source of her debilit... By: StemCell ARTS … Continue reading →

2.(January19, 2012) 3.(June 6, 2010) 4.(January21, 2010) 5.(December19, 2013) 6.(December11, 2013) Wu Stem Cells Medical Center (WSCMC) was named after Dr. Like Wu, the co-Founder, Chief Neurologist and Managing Director of the center. Using the unique stem cell technologies innovated by Dr. Wu, since 2005, he and his medical team have successfully treated over 2,000 patients from all over the world suffering from various neurological diseases, disorders, and injuries including Parkinson's disease, post-stroke, Batten's disease, ALS, MS, MSA, PSP, cerebral palsy, traumatic brain and spinal cord injuries, etc. This has laid a solid foundation for the application of stem cell technologies to treat these previously untreatable neurological diseases. To make a world of difference in the lives of patients and their families by integrating new medical technologies, care, education and research to provide the highest quality care and service to our diverse community. WSCMC will be one of the best stem cells medical centers in the world, known for advancing research and providing definitive diagnosis and treatment for our diverse community of patients with complex neurological diseases. Read more... Cerebral palsy Read more from the original source: Wu Stem Cells Medical Center - A Leading Medical Center for ... … Continue reading →